Cytomedix Inc.
416 Hungerford Drive
Suite 330
Rockville,
MD 20850
United States - Map
Phone: 240-499-2680
Fax: 240-499-2690
Web Site: http://www.cytomedix.com
| Cytomedix, Inc., a biotechnology company, engages in the development, sale, and licensing of regenerative biological therapies for wound care, inflammation, and angiogenesis primarily in the United States. The company provides the AutoloGel System, a device for the production of platelet rich plasma gel that is derived from the patientÂ’s own blood. Its products include the AutoloGel System Centrifuge II, the AutoloGel wound dressing Kits, and AutoloGel reagents kits. These products are used for the treatment of exuding wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers, as well as for the management of mechanically or surgically debrided wounds. The company also focuses on developing CT 112, which is an anti-inflammatory peptide. It markets its products primarily to health care providers, and licenses its patents to surgical medical device suppliers. Cytomedix, Inc. has licensing agreements with DePuy Spine, Inc.; Medtronic, Inc.; Harvest Technologies, Inc.; Perfusion Partners and Associates, Inc.; COBE Cardiovascular, Inc.; SafeBlood Technologies, Inc.; Biomet Biologics, Inc.; CellMedix, Inc.; and Smith and Nephew, Inc. The company was formerly known as Autologous Wound Therapy, Inc. and changed its name to Cytomedix, Inc. in 2000. Cytomedix, Inc. was founded in 1987 and is headquartered in Rockville, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Martin P. Rosendale , 52
Chief Exec. Officer |
$
198.00K | N/A | Mr. Andrew S. Maslan CPA, 39
Chief Financial Officer, Chief Accounting Officer and Corp. Controller |
N/A
| N/A | Mr. David E. Jorden CPA, CFA, 46
Exec. Director |
N/A
| N/A | Dr. Kshitij Mohan Ph.D, 63
Consultant |
N/A
| N/A | Ms. Carelyn P. Fylling RN, MSN, 62
VP of Professional Services |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.02% Nasdaq 
0.02 (4.17%) 
Profile
